Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520326-11-00

Enrollment

Registered

2025-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myeloid Leukemia (AML)

Brief summary

The 1-year leukemia -free survival (LFS) after allo-SCT

Interventions

DRUGTreosulfan Tillomed 5g polvere per soluzione per infusione

DRUGFLUDARABINE TEVA 25 mg/ml

DRUGsolution à diluer pour injectable ou perfusion

DRUGCICLOSPORIN

DRUGANTITHYMOCYTE IMMUNOGLOBULIN (RABBIT)

DRUGMETHOTREXATE

DRUGGrafalon 20 mg/ml concentrato per soluzione per infusione

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The 1-year leukemia -free survival (LFS) after allo-SCT	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026